Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1998-3-24
pubmed:abstractText
Women with locally unresectable and inflammatory breast carcinoma (IBC) have an approximately 30% 5-year disease-free survival (DFS) rate with conventional multimodality therapy. A short but dose-intensive multimodality phase II trial was designed in an attempt to improve outcome in stage IIIB disease. Mastectomy was performed after high-dose therapy to evaluate pathologic response to treatment.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0732-183X
pubmed:author
pubmed:issnType
Print
pubmed:volume
16
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1000-7
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed-meshheading:9508183-Adult, pubmed-meshheading:9508183-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:9508183-Bone Marrow Transplantation, pubmed-meshheading:9508183-Breast Neoplasms, pubmed-meshheading:9508183-Combined Modality Therapy, pubmed-meshheading:9508183-Doxorubicin, pubmed-meshheading:9508183-Female, pubmed-meshheading:9508183-Granulocyte Colony-Stimulating Factor, pubmed-meshheading:9508183-Hematopoietic Stem Cell Transplantation, pubmed-meshheading:9508183-Humans, pubmed-meshheading:9508183-Mastectomy, pubmed-meshheading:9508183-Middle Aged, pubmed-meshheading:9508183-Neoplasm Staging, pubmed-meshheading:9508183-Radiotherapy, pubmed-meshheading:9508183-Remission Induction, pubmed-meshheading:9508183-Survival Rate, pubmed-meshheading:9508183-Transplantation, Autologous
pubmed:year
1998
pubmed:articleTitle
High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma.
pubmed:affiliation
Department of Cancer Pharmacology, Dana-Farber Cancer Institute, Boston, MA, USA. layash@umich.edu
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't, Clinical Trial, Phase II